Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3β Signaling

Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3β Signaling

Sec-O-glucosylhamaudol (SOG), an active flavonoid compound derived from the root of Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk., exhibits analgesic, anti-inflammatory, and high 5-lipoxygenase (5-LO) inhibitory effects. However, its effect on osteoclastogenesis was unclear. We demonstrated...

Full description

Bibliographic Details
Main Authors:	Jinjin Cao, Ming-Xue Zhou, Xinyan Chen, Menglu Sun, Congmin Wei, Qisheng Peng, Zhou Cheng, Wanchun Sun, Hongbing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Immunology
Subjects:	Sec-O-glucosylhamaudol osteoclasts NFATc1 GSK3β 5-lipoxygenase AKT
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.880988/full

Similar Items

PEGylated magnetic nanographene oxide for targeted delivery of arsenic trioxide and sec-o-glucosylhamaudol in tumor treatment with improved dual-drugs synergistic effect
by: Jinlai Cheng, et al.
Published: (2023-06-01)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
by: Yunfei Zhan, et al.
Published: (2020-01-01)

Kynurenine Promotes RANKL-Induced Osteoclastogenesis In Vitro by Activating the Aryl Hydrocarbon Receptor Pathway
by: Nada H. Eisa, et al.
Published: (2020-10-01)

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
by: Gang Wang, et al.
Published: (2022-01-01)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
by: Huanhuan Hou, et al.
Published: (2020-02-01)

Water Extracts of Hull-less Waxy Barley (<i>Hordeum vulgare</i> L.) Cultivar ‘Boseokchal’ Inhibit RANKL-induced Osteoclastogenesis
by: Kwang-Jin Kim, et al.
Published: (2019-10-01)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
by: Mengbo Zhu, et al.
Published: (2021-09-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
by: Yosuke Akiba, et al.
Published: (2016-03-01)

Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway
by: Qi Zhang, et al.
Published: (2022-09-01)

Inhibitory Effects of Protopanaxadiol-Producing Transgenic Rice Seed Extracts on RANKL-Induced Osteoclast Differentiation
by: Yongjin Lee, et al.
Published: (2022-11-01)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
by: Jianbo He, et al.
Published: (2021-09-01)

Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity
by: Jianbo He, et al.
Published: (2023-12-01)

Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways
by: Yu Yuan, et al.
Published: (2020-03-01)

Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat
by: Ka-Yeon Lee, et al.
Published: (2019-08-01)

Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro
by: Chuandong Wang, et al.
Published: (2017-06-01)

Daily chemical evodiamine from Chinese prickly ash attenuates osteoclast differentiation through RANKL induced NFAT pathways
by: Lei Jiang, et al.
Published: (2017-10-01)

Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways
by: Xiao Chen, et al.
Published: (2018-12-01)

BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
by: Yufeng Zhang, et al.
Published: (2022-05-01)

Transcriptome Analysis Reveals That <i>Abeliophyllum distichum</i> Nakai Extract Inhibits RANKL-Mediated Osteoclastogenensis Mainly through Suppressing Nfatc1 Expression
by: Kyubin Lee, et al.
Published: (2020-08-01)

Nur77 prevents excessive osteoclastogenesis by inducing ubiquitin ligase Cbl-b to mediate NFATc1 self-limitation
by: Xiaoxiao Li, et al.
Published: (2015-07-01)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
by: Chang-hong Li, et al.
Published: (2021-12-01)

Osteostatin Inhibits M-CSF+RANKL-Induced Human Osteoclast Differentiation by Modulating NFATc1
by: Lidia Ibáñez, et al.
Published: (2022-08-01)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
by: Chang-hong Li, et al.
Published: (2023-07-01)

Elucidating the role of RBM5 in osteoclastogenesis: a novel potential therapeutic target for osteoporosis
by: Yuyang Zhang, et al.
Published: (2023-11-01)

Dieckol isolated from Eisenia bicyclis extract suppresses RANKL-induced osteoclastogenesis in murine RAW 264.7 cells
by: Su-Hyeon Cho, et al.
Published: (2022-01-01)

Identification of anti-osteoclastogenic compounds from Cleistocalyx operculatus flower buds and their effects on RANKL-induced osteoclastogenesis
by: Phuong Thao Tran, et al.
Published: (2019-09-01)

Concentration and Duration of Indoxyl Sulfate Exposure Affects Osteoclastogenesis by Regulating NFATc1 via Aryl Hydrocarbon Receptor
by: Wen-Chih Liu, et al.
Published: (2020-05-01)

Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss
by: Sang-Yong Han, et al.
Published: (2021-12-01)

The Inhibitory Role of Rab11b in Osteoclastogenesis through Triggering Lysosome-Induced Degradation of c-Fms and RANK Surface Receptors
by: Manh Tien Tran, et al.
Published: (2020-12-01)

Rab11A Functions as a Negative Regulator of Osteoclastogenesis through Dictating Lysosome-Induced Proteolysis of c-fms and RANK Surface Receptors
by: Yuka Okusha, et al.
Published: (2020-10-01)

Suppressive effects of (-)-tubaic acid on RANKL-induced osteoclast differentiation and bone resorption
by: Soomin Lim, et al.
Published: (2023-12-01)

Hexosamine Biosynthetic Pathway-Derived O-GlcNAcylation Is Critical for RANKL-Mediated Osteoclast Differentiation
by: Myoung Jun Kim, et al.
Published: (2021-08-01)

Emerging View on the Molecular Functions of Sec62 and Sec63 in Protein Translocation
by: Sung-jun Jung, et al.
Published: (2021-11-01)

<i>Eleutherococcus sessiliflorus</i> Inhibits Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Induced Bone Loss
by: Sang-Yong Han, et al.
Published: (2021-03-01)

Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
by: Yurui Jiao, et al.
Published: (2020-08-01)

Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and –independent autophagic responses
by: Guoyou Zhang, et al.
Published: (2019-10-01)

Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1–Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis
by: Ke Fang, et al.
Published: (2022-07-01)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
by: Yuria Jang, et al.
Published: (2021-01-01)

Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo
by: Cheng-Ming Wei, et al.
Published: (2018-07-01)

Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis
by: Minsun Kim, et al.
Published: (2020-02-01)